Jay David Caplan Sells 22,346 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 22,346 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.81, for a total value of $40,446.26. Following the completion of the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. This represents a 12.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jay David Caplan also recently made the following trade(s):

• On Monday, November 11th, Jay David Caplan sold 64,197 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total value of $158,566.59.

Fractyl Health Price Performance

GUTS stock opened at $1.53 on Wednesday. The business has a fifty day moving average of $2.05 and a two-hundred day moving average of $2.49. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The stock has a market cap of $73.59 million and a price-to-earnings ratio of -0.13. Fractyl Health, Inc. has a 52-week low of $1.52 and a 52-week high of $13.99.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. The business had revenue of $0.01 million for the quarter. As a group, research analysts anticipate that Fractyl Health, Inc. will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GUTS. Geode Capital Management LLC boosted its position in shares of Fractyl Health by 166.5% during the third quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after buying an additional 313,335 shares during the period. State Street Corp boosted its position in shares of Fractyl Health by 129.4% during the third quarter. State Street Corp now owns 113,415 shares of the company’s stock worth $287,000 after buying an additional 63,968 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after buying an additional 49,289 shares during the period. Barclays PLC boosted its position in shares of Fractyl Health by 1,754.7% during the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock worth $121,000 after buying an additional 45,219 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Fractyl Health during the third quarter worth $85,000.

Analyst Ratings Changes

Separately, Morgan Stanley cut their target price on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research note on Monday.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.